News provided by Smith & Nephew Nov 16, 2018MEMPHIS, Tenn., Nov. 16, 2018 /PRNewswire/ — Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, presented a number of compelling clinical outcomes around its flagship JOURNEY II BCS knee earlier this month at the American Association of Hip and Knee Surgeons (AAHKS). The announcement follows more than a dozen publications during the past year from various authors around the globe.1-14
In one of the largest multi-center retrospective patient cohorts ever studied, new clinical evidence represented excellent mid-term survivorship results on 2,059 patients with JOURNEY II BCS implants including:
- About 1% of patients required major revision out to 6 years.15
- No major or minor revision of any patient four years or more post-op.15
- Five year revision rate that was reported as 3.6% compared to 4.1% for the cemented posterior stabilized (PS) class in the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR).